A dual imaging approach may improve diagnosis and monitoring of prostate cancer

August 28, 2019

A new platform that combines two established imaging methods can peer into both the structure and molecular makeup of the prostate in men with prostate cancer. The technology is more sensitive and comprehensive compared to current "gold standard" methods, indicating it could allow clinicians to diagnose and monitor prostate cancers in real time with greater accuracy and confidence. Prostate cancer affects over 1.2 million people worldwide and is one of the most common malignancies in men. Most cases are diagnosed using biopsy and a method called transrectal ultrasound (TRUS), which uses sound waves to image the prostate and its surrounding tissues. However, TRUS cannot probe the prostate's molecular profile, meaning it misses key molecular markers and often gives false negatives and positives. To overcome these limitations, Sri-Rajasekhar Kothapalli and colleagues created TRUSPA, a device that integrates TRUS with a hybrid optical-ultrasound method named photoacoustic imaging. Combining these approaches allows TRUSPA to detect anatomical features of the prostate such as blood vessels in real time, as well as detailed molecular information within tumors. The platform worked as intended in mouse models of prostate cancer and in isolated human prostates and administering an FDA-approved dye enhanced image contrast. In an experiment with 20 male subjects, TRUSPA provided clear images of the prostate's anatomy - peering as deep as six centimeters into tissue - and could distinguish a malignant region of the prostate in one patient with advanced disease. Kothapalli et al. will investigate how TRUSPA could be developed to detect specific biomarkers of prostate cancer, which could further boost its accuracy and clinical potential.
-end-


American Association for the Advancement of Science

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.